MADISON, Wis.--(BUSINESS WIRE)--EraGen Biosciences Inc. today announced the appointment of industry veteran Gregory D. Rodgers as vice president of manufacturing.
Mr. Rodgers brings to EraGen more than 30 years of manufacturing and operating experience, including two decades of in vitro diagnostic device manufacturing experience. He has a unique breadth and depth of experience in manufacturing reagents and instruments, developing and executing manufacturing plans in an FDA-regulated environment, and manufacturing process development and engineering. He also has significant experience with manufacturing cost management and plant performance assessment.
Mr. Rodgers was most recently vice president and senior director of MonoGen Inc., a medical device and diagnostics company that served anatomic and molecular pathology laboratories. While at MonoGen, he was responsible for the design, development and validation of the high-volume manufacturing equipment used to make the company’s reagents. He also participated in the final design of the company’s laboratory instrument and reagents, resulting in improved manufacturability, serviceability and cost reduction.
Mr. Rodgers began and spent more than 20 years of his career at bioMérieux, a world leader in in vitro diagnostics, where he rose through the ranks to become vice president of the company’s North American operations. He was responsible for the manufacture of all of its reagents and instruments.
“We are delighted to welcome Greg to EraGen,” said Irene Hrusovsky, M.D., EraGen’s president and chief executive. “Greg’s leadership will be essential in continuing to advance the company’s manufacturing capabilities to support our in vitro diagnostic product development and rapidly accelerating volume growth. In addition, Greg’s experience augments our management team well. The collective leadership of our management team will continue to fuel and guide EraGen’s continuing dramatic growth.”
Mr. Rodgers’ colleagues on EraGen’s management team are leaders in regulatory affairs, sales and marketing, product development, business management and medical leadership. Their combined experience and significant accomplishments in the in vitro diagnostics industry poise the company for great success, Dr. Hrusovsky said.
“I’m excited to be joining EraGen at its inflection point and I’m looking forward to writing a new chapter of manufacturing excellence and capability at the company,” Mr. Rodgers said. “I’m pleased to be joining an outstanding, experienced management team and am enthusiastic about continuing to drive outstanding performance with them.”
About EraGen Biosciences
EraGen Biosciences develops, manufactures and markets molecular reagent products that are driving a new era in clinical diagnostics. The company’s in-market and pipeline products, based on its novel, patented MultiCode® platform chemistry, are the next generation of DNA- and RNA-based testing for the early detection of infectious diseases and genetic-based conditions. EraGen’s expanding menu of high quality, easy-to-use products position the company for leadership in the molecular diagnostics market. For more information, visit the EraGen website at www.eragen.com.